Recommendations for high-priority research on cancer-related fatigue in children and adults.

Published

Journal Article

Over the past decades, some scientific progress has been made in understanding and treating cancer-related fatigue (CRF). However, three major problems have limited further progress: lack of agreement about measurement, inadequate understanding of the underlying biology, and problems in the conduct of clinical trials for CRF. This commentary reports the recommendations of a National Cancer Institute Clinical Trials Planning Meeting and an ongoing National Cancer Institute working group to address these problems so that high-priority research and clinical trials can be conducted to advance the science of CRF and its treatment. Recommendations to address measurement issues included revising the current case definition to reflect more rigorous criteria, adopting the Patient Reported Outcomes Measurement Information System fatigue scales as standard measures of CRF, and linking legacy measures to the scales. With regard to the biology of CRF, the group identified the need for longitudinal research to examine biobehavioral mechanisms underlying CRF and testing mechanistic hypotheses within the context of intervention research. To address clinical trial issues, recommendations included using only placebo-controlled trial designs. setting eligibility to minimize sample heterogeneity or enable subgroup analysis, establishing a CRF severity threshold for participation in clinical trials, conducting dissemination trials of efficacious interventions (such as exercise), and combining nonpharmacologic and pharmacologic interventions to exploit the potential synergy between these approaches. Accomplishing these goals has the potential to advance the science of CRF and improve the clinical management of this troubling symptom.

Full Text

Duke Authors

Cited Authors

  • Barsevick, AM; Irwin, MR; Hinds, P; Miller, A; Berger, A; Jacobsen, P; Ancoli-Israel, S; Reeve, BB; Mustian, K; O'Mara, A; Lai, J-S; Fisch, M; Cella, D; National Cancer Institute Clinical Trials Planning Meeting,

Published Date

  • October 2013

Published In

Volume / Issue

  • 105 / 19

Start / End Page

  • 1432 - 1440

PubMed ID

  • 24047960

Pubmed Central ID

  • 24047960

Electronic International Standard Serial Number (EISSN)

  • 1460-2105

International Standard Serial Number (ISSN)

  • 0027-8874

Digital Object Identifier (DOI)

  • 10.1093/jnci/djt242

Language

  • eng